Zoetis Inc.
NYSE•ZTS
CEO: Ms. Kristin C. Peck
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2013-02-01
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Contact Information
Market Cap
$51.13B
P/E (TTM)
19.0
35.8
Dividend Yield
1.8%
52W High
$172.23
52W Low
$114.47
52W Range
Rank6
7.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 7.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$2.39B+0.00%
4-Quarter Trend
EPS
$1.38+0.00%
4-Quarter Trend
FCF
$732.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Income Rises 8% Net income attributable to Zoetis reached $2,673M in 2025, marking an 8% increase compared to 2024 results.
Total Revenue Grows 2% Total revenue was $9,467M in 2025, reflecting 2% growth driven by 4% price increases globally.
Companion Animal Sales Strong Companion animal revenue grew 5% to $6,587M, led by Simparica and Apoquel franchises performance.
Diluted EPS Up 10% Diluted EPS reached $6.02 for 2025, showing a 10% improvement over the prior year's $5.47.
Risk Factors
Generic Competition Erodes Sales Generic competition caused Draxxin sales to decline 66% in the U.S. market, impacting overall revenue stability.
Livestock Revenue Declines Livestock revenue fell 5% to $2,764M in 2025, partially due to the MFA divestiture impact.
Substantial Debt Obligations Total unsecured indebtedness stands at $9.2B, increasing vulnerability to adverse economic and industry conditions.
Regulatory Scrutiny Increasing Increased regulatory scrutiny concerning antibacterial use and environmental impact may necessitate additional time and resources.
Outlook
ERP Transition Underway Multi-year ERP system update is progressing, aiming for seamless financial consolidation and regulatory compliance in 2026.
FY Alignment Expected 2026 Expect to eliminate the one-month lag for International Subsidiaries in 2026, aligning year-ends to December 31.
Continued Innovation Focus Strategy emphasizes leading through innovation across the diverse portfolio, leveraging R&D capabilities and external collaborations.
Capital Allocation Priorities Board authorized up to $6B share repurchase program; $2.4B remains available as of year-end 2025.
Peer Comparison
Revenue (TTM)
$325.78B
$274.95B
$199.13B
Gross Margin (Latest Quarter)
89.3%
85.0%
75.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| GSK | $105.02B | 13.8 | 37.2% | 29.0% |
| REGN | $76.62B | 16.8 | 14.8% | 6.7% |
| CI | $70.67B | 11.8 | 14.5% | 19.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.4%
Moderate Growth
4Q Net Income CAGR
-1.5%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 30, 2026
EPS:$1.61
|Revenue:$2.31B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data